Michael Sinclair - 23 Aug 2021 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Role: Director, 10%+ Owner
Signature: /s/ Michael Sinclair
Issuer symbol: N/A
Transactions as of: 23 Aug 2021
Net transactions value: -$1,606,674
Form type: 4
Filing time: 25 Aug 2021, 16:38:32 UTC
Next filing: 06 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OPNT	Common Stock, par value $0.001 per share	Options Exercise	$325,620	+65,124	+45%	$5.00^*	209,194	23 Aug 2021	Direct
transaction	OPNT	Common Stock, par value $0.001 per share	Sale	$1,074,546	-65,124	-31%	$16.50	144,070	23 Aug 2021	Direct	F1
transaction	OPNT	Common Stock, par value $0.001 per share	Options Exercise	$173,035	+34,607	+24%	$5.00^*	178,677	24 Aug 2021	Direct
transaction	OPNT	Common Stock, par value $0.001 per share	Sale	$543,676	-34,607	-19%	$15.71	144,070	24 Aug 2021	Direct	F2
transaction	OPNT	Common Stock, par value $0.001 per share	Options Exercise	$251,345	+50,269	+35%	$5.00^*	194,339	25 Aug 2021	Direct
transaction	OPNT	Common Stock, par value $0.001 per share	Sale	$738,452	-50,269	-26%	$14.69	144,070	25 Aug 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OPNT	Options	Options Exercise	$0	-65,124	-43%	$0.000000	84,876	23 Aug 2021	Common Stock, par value $0.001 per share	65,124	$5.00	Direct	F4
transaction	OPNT	Options	Options Exercise	$0	-34,607	-41%	$0.000000	50,269	24 Aug 2021	Common Stock, par value $0.001 per share	34,607	$5.00	Direct	F4
transaction	OPNT	Options	Options Exercise	$0	-50,269	-100%	$0.000000^*	0	25 Aug 2021	Common Stock, par value $0.001 per share	50,269	$5.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.